CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The AD-VEC project focuses on developing new adenoviral vectors for medical applications targeting cardiovascular and infectious diseases. By collaborating across academia and industry, it aims to engineer and evaluate these vectors for improved therapeutic outcomes in areas of unmet clinical need.
We propose a programme (AD-VEC) involving two industrial and three academic partners with the aim to identify new adenoviral vectors as vehicles in novel medical applications for cardiovascular disease and infectious disease.This will be
achieved through broad knowledge exchange between partners with complimentary and cutting edge technological and in-depth skills relating to adenovirus phylogeny, biology and pathology in order to explore and exploit adenovirus existing in
nature as new vectors…
THE UNIVERSITY OF EDINBURGH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Janssen Vaccines (f.k.a. Crucell Holland B.V.)
Netherlands, Leiden
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Netherlands, Leiden
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Sweden, Umea
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
